Torosian M H
Department of Surgery, University of Pennsylvania School of Medicine, Philadelphia.
Surg Gynecol Obstet. 1988 Jun;166(6):567-79.
This state-of-the-art review identifies the clinical usefulness and limitations of currently available tumor markers. The role of specific tumor markers in screening, assessing extent of disease and monitoring the response of the tumor to antineoplastic therapy is discussed. Recent technologic advances, including monoclonal antibodies and genetic analysis, may identify additional tumor markers and provide insight into the developmental process of neoplasia by characterizing the biologic changes associated with malignant disease.
这篇前沿综述确定了当前可用肿瘤标志物的临床实用性和局限性。讨论了特定肿瘤标志物在筛查、评估疾病范围以及监测肿瘤对抗肿瘤治疗反应中的作用。包括单克隆抗体和基因分析在内的最新技术进展,可能会识别出更多的肿瘤标志物,并通过描述与恶性疾病相关的生物学变化,深入了解肿瘤形成的发展过程。